In vitro potency evaluations of various piperacillin/tazobactam generic products compared with the contemporary branded (Zosyn®, Wyeth) formulation

被引：22

作者：

Jones, Ronald N. ^{[1
,2
]}

Fritsche, Thomas R. ^{[1
]}

Moet, Gary J. ^{[1
]}

机构：

[1] JMI Labs, N Liberty, IA 52317 USA

[2] Tufts Univ, Sch Med, Boston, MA 02111 USA

来源：

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2008年 / 61卷 / 01期

关键词：

piperacillin/tazobactam; genetics; branded agents; activity in vitro;

D O I：

10.1016/j.diagmicrobio.2007.12.010

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Twenty-three generic intravenous piperacillin/tazobactam products were compared for in vitro activity to the branded formulation (Zosyn(R), Wyeth, Philadelphia, PA) by disk diffusion and incremental broth microdilution assay methods. All but I lot demonstrated significantly decreased activity (-5 to -35%), necessitating further investigations regarding the chemical purity, potency, and therapeutic equivalence of these products worldwide. The average -16% activity across all generic lots was equivalent to underdosing piperacillin/tazobactam by 2.6 g daily for serious clinical infections (4.5 g Q6 h). (C) 2008 Elsevier Inc. All rights reserved.

引用

页码：76 / 79

页数：4

共 13 条

[1]

*CLIN LAB STAND I, 2006, M100S16 CLSI

[2]

CLSI, 2007, M100S17 CLSI

[3] STUDIES TO OPTIMIZE THE INVITRO TESTING OF PIPERACILLIN COMBINED WITH TAZOBACTAM (YTR-830) [J].

JONES, RN ;

BARRY, AL .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1989, 12 (06) :495-510

[4]

Kuck N A, 1989, J Chemother, V1, P105

[5] Pharmaceutical quality of ceftriaxone generic drug products compared with Rocephin® [J].

Lambert, PA ;

Conway, BR .

JOURNAL OF CHEMOTHERAPY, 2003, 15 (04) :357-368

[6]

*PACK INS, 2007, ZOS

[7] Generic substitution of itraconazole resulting in subtherapeutic levels and resistance [J].

Pasqualotto, Alessandro Comaru ;

Denning, David W. .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 30 (01) :93-94

[8]

RODRIGUEZ CA, 2004, 44 INT C ANT AG CHEM, P28

[9] Predicting the clinical efficacy of generic formulations of ceftriaxone [J].

Schito, GC ;

Keenan, MHJ .

JOURNAL OF CHEMOTHERAPY, 2005, 17 :33-40

[10]

Wayne P., 2006, CLSIM7-A7

← 1 2 →